tiprankstipranks
Vaxcyte initiated with an Outperform at TD Cowen
The Fly

Vaxcyte initiated with an Outperform at TD Cowen

TD Cowen analyst Boris Peaker initiated coverage of Vaxcyte with an Outperform rating and no price target. Vaxcyte is developing a 24-valent pneumococcal conjugate vaccine VAX-24 in adults and infants, which has the potential to become a market leading PCV, addressing a $10B total addressable market, the analyst tells investors in a research note.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on PCVX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles